A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4 Meeting Abstract
| Authors: | Janjigian, Y. Y.; Lloyd, C.; de Giorgio-Miller, V. G.; Chang, Y. T.; Lee, J. |
| Abstract Title: | A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4 |
| Meeting Title: | ESMO Asia Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2024 Dec 6-8 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-12-01 |
| Start Page: | S1502 |
| End Page: | S1503 |
| Language: | English |
| ACCESSION: | WOS:001401985200252 |
| DOI: | 10.1016/j.annonc.2024.10.282 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 264TiP -- Source: Wos |
